Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04422132 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoints added 1 → 4 primary endpoints
See other at-risk trials from Weill Medical College of Cornell University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 5 more changesShow less
    • Results posted: Oct 14, 2026
    • Enrollment target: estimated 134 to confirmed 137
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: 4 to 21
    • Publications: details revised at 1 of 1 entry
  2. Study completion date: Dec 31, 2028 to Dec 31, 2033v9
  3. Study completion date: Dec 31, 2033 to Dec 31, 2028v8
  4. Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Study completion date: Dec 31, 2025 to Dec 31, 2033
    v7
  5. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Eligibility criteria shortened, about 16 wordsv5
  2. Site contact updated
    • Eligibility criteria expanded, about 4 words
    v4
  3. Site contact updatedv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 5, 2020 to Sep 24, 2020
    • Site details revised
    • Collaborators expanded, about 2 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to compare urinary and bowel side effects of hypofractionated radiotherapy in 20 treatments (4 weeks) to ultra-hypofractionated radiotherapy in 5 treatments (2 weeks) for prostate cancer that has returned after prostatectomy. The investigators are also interested in looking at time to progression and the quality of life (health scores).
Trial Details
NCT Number NCT04422132
Lead Sponsor Weill Medical College of Cornell University
Collaborators: Viewray Inc.
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 137 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov